Skip to main content
Retour
DGX logo

Quest Diagnostics Incorporated

Qualité des données : 100%
DGX
NYSE Healthcare Medical - Diagnostics & Research
196,10 €
▲ 0,50 € (0,26%)
Cap. Boursière : 21,81B
Fourchette du Jour
193,81 € 197,03 €
Fourchette 52 Semaines
157,20 € 213,50 €
Volume
384 942
Moyenne 50J / 200J
195,42 € / 183,46 €
Clôture Précédente
195,60 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 22,0 0,3
P/B 3,0 2,9
ROE % 14,2 3,7
Net Margin % 9,0 3,8
Rev Growth 5Y % 0,6 10,0
D/E 1,0 0,2

Objectif de Cours des Analystes

Hold
215,10 € +9.7%
Low: 200,00 € High: 235,00 €
P/E Prévisionnel
18,4
BPA Prévisionnel
10,64 €
Croissance BPA (est.)
+0,0%
CA Est.
12 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2029 13,89 €
13,50 € – 14,19 €
13 B 2
FY2028 12,49 €
11,82 € – 13,50 €
13 B 7
FY2027 11,47 €
11,22 € – 11,85 €
12 B 12

Points Clés

Revenue grew 0,57% annually over 5 years — modest growth
ROE of 14,22% — decent returns on equity
Generating 1,36B in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 11,21%
Cash machine — converts 137,00% of earnings into free cash flow
Capital efficient — spends only 4,78% of revenue on capex

Croissance

Revenue Growth (5Y)
0,57%
Revenue (1Y)11,78%
Earnings (1Y)13,89%
FCF Growth (3Y)25,42%

Qualité

Return on Equity
14,22%
ROIC8,53%
Net Margin8,99%
Op. Margin14,53%

Sécurité

Debt / Equity
0,96
Current Ratio1,04
Interest Coverage6,07

Valorisation

P/E Ratio
21,99
P/B Ratio3,04
EV/EBITDA17,66
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 11,78% Revenue Growth (3Y) 9,21%
Earnings Growth (1Y) 13,89% Earnings Growth (3Y) 7,78%
Revenue Growth (5Y) 0,57% Earnings Growth (5Y) -16,03%
Profitability
Revenue (TTM) 11,04B Net Income (TTM) 992,00M
ROE 14,22% ROA 6,11%
Gross Margin 31,93% Operating Margin 14,53%
Net Margin 8,99% Free Cash Flow (TTM) 1,36B
ROIC 8,53% FCF Growth (3Y) 25,42%
Safety
Debt / Equity 0,96 Current Ratio 1,04
Interest Coverage 6,07 Dividend Yield 0,02%
Valuation
P/E Ratio 21,99 P/B Ratio 3,04
P/S Ratio 1,98 PEG Ratio 1,42
EV/EBITDA 17,66 Dividend Yield 0,02%
Market Cap 21,81B Enterprise Value 28,31B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 11,04B 9,87B 9,25B 9,88B 10,79B
Net Income 992,00M 871,00M 854,00M 946,00M 2,00B
EPS (Diluted) 8,75 7,69 7,52 7,98 15,53
Gross Profit 3,52B 3,24B 3,07B 3,43B 4,21B
Operating Income 1,60B 1,35B 1,26B 1,43B 2,38B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 16,23B 16,15B 14,02B 12,84B 13,61B
Total Liabilities 8,94B 9,26B 7,60B 6,83B 7,05B
Shareholders' Equity 7,17B 6,78B 6,31B 5,89B 6,44B
Total Debt 6,92B 7,09B 5,50B 4,71B 4,77B
Cash & Equivalents 420,00M 549,00M 686,00M 315,00M 872,00M
Current Assets 2,38B 2,39B 2,37B 1,90B 2,74B
Current Liabilities 2,28B 2,17B 1,82B 1,55B 1,75B

Scores de Stratégies

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#614 of 1052
40

Activité Récente

Entré Cash Flow Compounder
Mar 24, 2026